X4 Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:48Q0 Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Role	Shares	Max Price
16 May 25	Buy€2,298	Mark Baldry	Individual		1,032	€2.23
15 Nov 24	Buy€18,249	Mark Baldry	Individual		1,168.33	€19.25

Insider Trading Volume

Insider Buying: 48Q0 insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 48Q0?
Owner Type	Number of Shares	Ownership Percentage
Individual Insiders	348,976	6.03%
VC/PE Firms	1,063,417	18.4%
General Public	2,084,662	36%
Institutions	2,291,631	39.6%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 60.78% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
9.74%	Bain Capital Life Sciences Investors, LLC	563,858	€1.7m	0%	0.27%
8.63%	New Enterprise Associates, Inc.	499,559	€1.5m	0%	0.1%
6.58%	BlackRock, Inc.	381,009	€1.1m	3.34%	no data
4.65%	The Vanguard Group, Inc.	268,916	€804.3k	-1.63%	no data
4.21%	Acorn Bioventures	243,688	€728.9k	0%	0.54%
4.03%	Kingdon Capital Management, L.L.C.	233,333	€697.9k	41.8%	0.15%
3.9%	OrbiMed Advisors LLC	225,883	€675.6k	-5%	0.01%
3.67%	Anders Hove	212,237	€634.8k	0%	no data
2.9%	UBS Asset Management AG	167,905	€502.2k	446%	no data
2.08%	Geode Capital Management, LLC	120,655	€360.9k	3.5%	no data
1.76%	State Street Global Advisors, Inc.	101,835	€304.6k	-0.07%	no data
1.29%	Ensign Peak Advisors, Inc.	74,521	€222.9k	-12.2%	no data
1.17%	Pale Fire Capital SE	67,845	€202.9k	45.2%	0.02%
1.01%	Medical Strategy GmbH, Asset Management Arm	58,657	€175.4k	0%	0.01%
0.99%	Susquehanna International Group, LLP, Asset Management Arm	57,078	€170.7k	-9.28%	no data
0.72%	Northern Trust Global Investments	41,793	€125.0k	-7.64%	no data
0.63%	Paula Ragan	36,246	€108.4k	9.4%	no data
0.5%	Christophe Arbet-Engels	28,807	€86.2k	0%	no data
0.44%	Mark Baldry	25,337	€75.8k	488%	no data
0.4%	AXA Investment Managers S.A.	23,037	€68.9k	-77.5%	no data
0.37%	Point72 Asset Management, L.P.	21,666	€64.8k	0%	no data
0.33%	Morgan Stanley, Investment Banking and Brokerage Investments	19,000	€56.8k	3.55%	no data
0.28%	Mary DiBiase	16,366	€49.0k	8.61%	no data
0.28%	Charles Schwab Investment Management, Inc.	16,050	€48.0k	9.89%	no data
0.22%	Arthur Taveras	12,934	€38.7k	0%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/28 12:00
End of Day Share Price	2025/04/25 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

X4 Pharmaceuticals, Inc. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Leah Rush Cann	Brookline Capital Markets
Arlinda Lee	Canaccord Genuity
Kristen Kluska	Cantor Fitzgerald & Co.